Astrocytes and glaucomatous neurodegeneration

Experimental Eye Research

Volumn 157, Issue , 2017, Pages 1-4

  Tamm, Ernst R ^a   Dowling, John E ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ASTROCYTE; BIOMECHANICS; BLINDNESS; CATARACT; DRUSEN; EDITORIAL; GLAUCOMA; HOMEOSTASIS; HUMAN; INTRAOCULAR PRESSURE; MOLECULAR BIOLOGY; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OPTIC DISK; OPTIC NERVE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RETINA DISEASE; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT; DEGENERATIVE DISEASE; NERVE FIBER; OPTIC NERVE DISEASE; PATHOLOGY; RETINA GANGLION CELL;

ASTROCYTES; GLAUCOMA; HUMANS; NERVE FIBERS; NEURODEGENERATIVE DISEASES; OPTIC DISK; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS;

EID: 85015068156     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2017.02.013     Document Type: Editorial

References (20)

1. Boland, M.V., Ervin, A.M., Friedman, D.S., Jampel, H.D., Hawkins, B.S., Vollenweider, D., Chelladurai, Y., Ward, D., Suarez-Cuervo, C., Robinson, K.A., Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern Med. 158 (2013), 271–279.
2. Calkins, D.J., Pekny, M., Cooper, M.L., Benowitz, L.I., The Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. The challenge of regenerative therapies for the optic nerve in glaucoma. Exp. Eye Res. 157 (2017), 28–33.
3. Collaborative Normal-Tension Glaucoma Study Group, Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126 (1998), 487–497.
4. Collaborative Normal-Tension Glaucoma Study Group, The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group Am. J. Ophthalmol. 126 (1998), 498–505.
5. Foster, P.J., Buhrmann, R., Quigley, H.A., Johnson, G.J., The definition and classification of glaucoma in prevalence surveys. Br. J. Ophthalmol. 86 (2002), 238–242.
6. Howell, G.R., Libby, R.T., Jakobs, T.C., Smith, R.S., Phalan, F.C., Barter, J.W., Barbay, J.M., Marchant, J.K., Mahesh, N., Porciatti, V., Whitmore, A.V., Masland, R.H., John, S.W., Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J. Cell Biol. 179 (2007), 1523–1537.
7. Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish, R.K. 2nd, Wilson, M.R., Gordon, M.O., The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120 (2002), 701–713 discussion 829–730.
8. Kingman, S., Glaucoma is second leading cause of blindness globally. Bull. World Health Organ 82 (2004), 887–888.
9. Leske, M.C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L., Komaroff, E., Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121 (2003), 48–56.
10. Levin, L.A., Quigley, H.A., Crowe, M.E., The Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Neuroprotection for glaucoma: requirements for clinical translation. Exp. Eye Res. 157 (2017), 34–37.
11. Quigley, H.A., Glaucoma. Lancet 377 (2011), 1367–1377.
12. Quigley, H.A., Addicks, E.M., Green, W.R., Maumenee, A.E., Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol. 99 (1981), 635–649.
13. Quigley, H.A., Broman, A.T., The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90 (2006), 262–267.
14. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G.P., Mariotti, S.P., Global data on visual impairment in the year 2002. Bull. World Health Organ 82 (2004), 844–851.
15. Stowell, C., Burgoyne, C., Tamm, E.R., Ethier, C.R., The Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Biomechanical aspects of axonal damage in glaucoma: a brief review. Exp. Eye Res. 157 (2017), 13–19.
16. Tamm, E.R., Ethier, C.R., The Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Biological aspects of axonal damage in glaucoma: a brief review. Exp. Eye Res. 157 (2017), 5–12.
17. Tamm, E.R., Schmetterer, L., Grehn, F., Status and perspectives of neuroprotective therapies in glaucoma: the European glaucoma society white paper. Cell Tissue Res. 353 (2013), 347–354.
18. Tham, Y.C., Li, X., Wong, T.Y., Quigley, H.A., Aung, T., Cheng, C.Y., Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121 (2014), 2081–2090.
19. The AGIS Investigators, The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130 (2000), 429–440.
20. Williams, P.A., Marsh-Armstrong, N., Howell, G.R., The Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Neuroinflammation in glaucoma: a new opportunity. Exp. Eye Res. 157 (2017), 20–27.